Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

Progress in ovarian cancer treatment lags behind other tumor types. With diagnosis usually
at an advanced stage, there is a high demand for reliable prognostic biomarkers capable of …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

Breast cancers are complex cellular ecosystems where heterotypic interactions play central
roles in disease progression and response to therapy. However, our knowledge of their …

Distant metastasis remains the major cause of morbidity for breast cancer. Individuals with
liver or brain metastasis have an extremely poor prognosis and low response rates to anti …

Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …

Metabolic reprogramming toward glycolysis is a hallmark of cancer malignancy. The
molecular mechanisms by which the tumor glycolysis pathway promotes immune evasion …

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …